Clinical Trial Update: 24-hour Efficacy of AR-12286 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the 24-hour efficacy of AR-12286 for open-angle glaucoma and ocular hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• AR-12286

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED